Drug Profile
AB 8939
Alternative Names: AB-8939Latest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator AB Science
- Class Antineoplastics; Imidazolidines; Oxazoles; Small molecules
- Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia
Most Recent Events
- 07 Mar 2024 AB Science plans a phase II trial of AB 8939 for Acute myeloid leukaemia in 2025
- 15 Mar 2023 Efficacy and adverse events data from a phase I/II trial in acute myeloid leukemia released by AB Science
- 13 Mar 2023 Efficacy and adverse events data from a phase I/II trial in Acute myeloid leukemia released by AB Science